drugset
drugset / Trial / NCT05897424

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

NCT05897424 ↗

Phase 2 Active not recruiting 185 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Timeline

Start
2024-06-20
Primary completion
2028-06-30
Completion
2028-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SAR447537 Protein / enzyme biologic — Intravenous

Indications

alpha 1-antitrypsin deficiency pulmonary emphysema